Epigenetic Modulating Compounds as Potential Therapeutic Agents for Treatment of Oesophageal Cancer.

Posted on: 15 Jun 2018

Epigenetic Modulating Compounds as Potential Therapeutic Agents for Treatment of Oesophageal Cancer.

 

 

Principal Investigator: Dr. Orla P Barry and Dr. Sharon McKenna

 

Oesophageal cancer is highly aggressive and with it being an exceptionally drug resistant tumour it is often a fatal malignancy. Although surgery is the best modality in terms of local control, outcomes following resection for oesophageal cancer remain unsatisfactory because of locoregional and distant recurrence. Thus, investigation(s) of alternative strategies in the fight against oesophageal cancer is wholly warranted and timely. The proposed plan of work in this application will extend upon our previous findings.

The application of epigenetic drugs in solid tumours, including GI tumours, is just beginning to emerge coupled with the increasing knowledge of the cancer epigenome. Recent whole genome and whole exome sequencing in oesophageal cancer has now placed this cancer to the fore as a disease of widespread epigenetic dysregulation. Furthermore, our work outlined here on epigenetic drug-induced re-expression of tumour suppressor genes may also influence future optimal treatment strategies and predict responses in oesophageal cancer patients (O’ Callaghan, C., et al., Anticancer Drugs, 2015, 26, 46-55). As we will be testing classes of drugs that have either been approved – or have approved analogues, the potential for clinical translation is high. Overall we expect that this research would tie in with BCR’s priorities on poor prognosis cancers and translational research.

 

 

© Site Designed by Granite Digital